Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia. NODE 301 and RAPID Studies

NCT03464019 is registered in ClinicalTrials.gov with Milestone Pharmaceuticals Inc. as lead sponsor.

NCT NCT03464019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03464019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia. NODE 301 and RAPID Studies
Lead sponsor
Milestone Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Terminated
Start date
June 18, 2018
Completion date
January 20, 2023
Enrollment
1,097 (actual)
Sites
161

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal supraventricular tachycardia